Guggenheim lifted the price target for the company from $33 to $35 while maintaining a Buy rating. The firm views the acquisition of Metsera, Inc. positively, highlighting gains in the oncology portfolio and a strategic re-entry into the obesity drug market. This move is seen as a competitive strength, contrasting with pressures faced by a rival in the GLP-1 space. The company is positioned as a compelling low-volatility, large-cap investment with a promising pipeline.